PBMs, FTC

PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
PBMs made more than $7B marking up specialty generics: FTC
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
Top three insurers reaped $7.3 billion through their drug middlemen’s markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ prescription price hikes of 1,000% or more.
FTC: Pharmacy benefit managers inflated drug prices by $7.3B
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies,
MedCity News3d
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Rolling Out1d
Troubling FTC probe reveals PBMs’ price-gouging tactics
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
pharmaphorum3d
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
New legislation aims to prevent PBMs from controlling drug pricing and pharmacy ownership
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
The FTC Finds United Health’s OptumRX Is Engaged In Widespread Price Gouging
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
More Litigation Coming? Insulin MDL Gets Boost from FTC Report
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
Insurancenewsnet.com1d
PBMs reaped substantial profits from dispensing prescription drugs, FTC finds
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...